文献速递生殖医学

超越外观:全面描述低质量囊胚在非整倍体检测周期中对提高活产率的临床贡献

Looking past the appearance: a comprehensive description of the clinical contribution of poor-quality blastocysts to increase live birth rates during cycles with aneuploidy testing.
PubMed 文献 · Hum Reprod · 2019-01-01

该观察性队列研究纳入2013年4月至2018年5月一家私立IVF中心的2757个PGT-A取卵周期,比较1497个低质量囊胚(PQB)与5250个非PQB的胚胎学、染色体和临床特征。PQB发育更慢、整倍体率更低(23.5% vs 51%,调整OR 0.36),整倍体PQB移植后着床率更低(16.9% vs 52.3%)、流产率更高(36.4% vs 13.9%)、活产率更低(10.8% vs 44.6%,调整OR 0.22),但临床使用PQB可使活产数总体增加2.6%。

要点

  • PQB整倍体率23.5%低于非PQB的51%(调整OR 0.36)。
  • 整倍体PQB移植活产率10.8%低于非PQB的44.6%(调整OR 0.22)。
  • 使用PQB可使活产数总体增加2.6%,获益最大者为>42岁或同胞非PQB极少者。

核心结论

  • PQB预后劣于同胞非PQB,但其临床使用可使PGT-A后可获得的活产数总体增加2.6%。

研究设计与样本

  • 观察性队列研究,纳入2013年4月至2018年5月一家私立IVF中心2757个PGT-A取卵周期,平均母亲年龄39.6±3.3岁。
  • 共获得1497个PQB和5250个非PQB(≥BB,按Gardner和Schoolcraft分类),比较胚胎学、染色体和临床特征并校正显著混杂因素。

主要发现

  • PQB较非PQB发育更慢:第5天10.1% vs 43.9%,第6天60.5% vs 50.8%,第7天29.4% vs 5.2%。
  • PQB整倍体率23.5% vs 非PQB 51%,调整OR 0.36。
  • 移植的整倍体PQB 195个 vs 非PQB 1697个,着床率16.9% vs 52.3%,每临床妊娠流产率36.4% vs 13.9%,活产率10.8% vs 44.6%(调整OR 0.22)。
  • 每活检PQB的整倍体冻融单胚胎移植后估计流产风险1.5%、活产机会2.6%;非PQB分别为3.7%和22.8%。
  • PQB使≥1个囊胚活检的周期增加12.4%,使≥1个活产的周期增加2.6%;18名妇女仅通过PQB获得其唯一活产,聚集于>42岁和/或同胞非PQB无或极少者(1.1±1.1,范围0-3)。

临床怎么用

  • 作者认为,若纳入PQB,推荐进行PGT-A。
  • 作者指出,应告知女性差的形态学不自行定义胚胎不可存活,尽管PQB活产机会降低。

局限性

  • PQB的临床获益被低估,因其为移植最后选择,且本分析仅涉及首次活产。
  • 每临床妊娠流产率较高可能是预后较差患者接受整倍体PQB单胚胎移植的结果,此选择需进一步研究。
  • 需以前瞻性非选择方式进行成本效益分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which are the clinical benefits and risks of including poor-quality blastocysts (PQBs) in the cohort of biopsied embryos during a cycle with preimplantation genetic testing for aneuploidies (PGT-A)? SUMMARY ANSWER: PQBs show a worse prognosis with respect to sibling non-PQBs, but their clinical use allows an overall 2.6% increase in the number of live births (LBs) achievable after PGT-A. WHAT IS KNOWN ALREADY: PQBs (<BB according to Gardner and Schoolcraft's classification) are generally disregarded for clinical use and/or research purposes. Therefore, limited data exist in literature to estimate the benefits and risks deriving from the transfer of a PQB. In Italy, the law imposes the transfer or cryopreservation of all embryos, unless proven not viable. This regulation has allowed the production of a large amount of data regarding poor-quality embryos. Previous reports outlined a lower chance of euploidy and implantation for PQBs. Yet, a comprehensive picture of their real clinical contribution is missing. STUDY DESIGN, SIZE, DURATION: This observational cohort study including 2757 oocyte retrievals for PGT-A (mean maternal age, 39.6 ± 3.3 years) conducted at a private IVF centre between April 2013 and May 2018. A total of 1497 PQBs were obtained and their embryological, chromosomal and clinical features were compared to 5250 non-PQBs (≥BB according to Gardner and Schoolcraft's classification) and adjusted for all significant confounders. After defining the overall increase in LBs due to PQBs, we outlined the population of patients who might benefit the most from their clinical use. PARTICIPANTS/MATERIALS, SETTING, METHODS: ICSI cycles, involving ovarian stimulation, blastocyst culture, trophectoderm biopsy, vitrification, comprehensive chromosome testing and vitrified-warmed euploid single embryo transfers (SETs), were conducted. Overall analyses and sub-analyses in populations of patients clustered according to maternal age at retrieval and size of the cohort of sibling non-PQBs were performed. Finally, the risk of miscarriage and the chance of LB per biopsied PQB and non-PQB were estimated. MAIN RESULTS AND THE ROLE OF CHANCE: PQBs allowed a 12.4% increase in the cycles where ≥1 blastocyst was biopsied. To date, we report a concurrent 2.6% increase in the cycles resulting in ≥1 LB. On average 0.7 ± 0.9 (range, 0-9) PQBs were obtained per cycle for biopsy, including 0.2 ± 0.4 (range, 0-5) euploid PQBs. Maternal age solely correlates with the prevalence of PQBs from both overall and cycle-based analyses. Indeed, the patients who benefit the most from these embryos (i.e. 18 women achieving their only LBs thanks to PQBs) cluster among women older than 42 years and/or those with no or few sibling non-PQBs (1.1 ± 1.1; range, 0-3). The 1497 PQBs compared to the 5250 non-PQBs showed slower development (Day 5, 10.1% versus 43.9%; Day 6, 60.5% versus 50.8%; Day 7, 29.4% versus 5.2%) and lower euploidy rates (23.5% versus 51%; adjusted OR, 0.36). Among the 195 and 1697 transferred euploid PQBs and non-PQBs, the former involved a lower implantation rate (16.9% versus 52.3%) and a higher miscarriage rate per clinical pregnancy (36.4% versus 13.9%), therefore resulting in a lower LB rate (LBR, 10.8% versus 44.6%; adjusted OR, 0.22). Based on these rates, we estimated an overall 1.5% risk of miscarriage and 2.6% chance of LB after euploid vitrified-warmed SET per each biopsied PQB. The same estimates for non-PQBs were 3.7% and 22.8%. LIMITATIONS, REASONS FOR CAUTION: The clinical benefit of PQBs is underestimated since they are the last option for transfer and this analysis entailed only the first LB. The higher miscarriage rate per clinical pregnancy here reported might be the consequence of a population of patients of poorer prognosis undergoing the SET of euploid PQBs, an option that requires further investigation. Finally, a cost-benefit analysis is needed in a prospective non-selection fashion. WIDER IMPLICATIONS OF THE FINDINGS: PQBs show higher aneuploidy rates. If to be included, PGT-A is recommended. When selected against aneuploid-PQBs, euploid ones could still involve a worse prognosis, yet, their LBR is not negligible. Women should be informed that a poor morphology does not define a non-viable embryo per se, although PQBs show a reduced chance of resulting in an LB. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. The authors have no conflict of interest related to this study. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cimadomo D, Soscia D, Vaiarelli A, et al. Looking past the appearance: a comprehensive description of the clinical contribution of poor-quality blastocysts to increase live birth rates during cycles with aneuploidy testing. Hum Reprod. 2019. PMID: 31247100. doi:10.1093/humrep/dez078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。